Derivatives of 3-sec-butyl-1-oxo-2,3-dihydroisoquinoline as inhibitors of μ-calpain

ChemMedChem

Volumn 1, Issue 7, 2006, Pages 710-714

  Chicharro, Roberto ^a   Alonso, Mercedes ^a   Mazo, M Teresa ^a   Arán, Vicente J ^b   Herradón, Bernardo ^a  

^a INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Calpain; Inhibitors; Isoquinoline; Peptide heterocycle hybrids; Peptidomimetics

Indexed keywords

3 SEC BUTYL 1 OXO 2,3 DIHYDROISOQUINOLINE; 3-SEC-BUTYL-1-OXO-2,3-DIHYDROISOQUINOLINE; CALPAIN; CYSTEINE PROTEINASE INHIBITOR; ISOQUINOLINE DERIVATIVE; MU CALPAIN; MU-CALPAIN;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; SYNTHESIS;

CALPAIN; CYSTEINE PROTEINASE INHIBITORS; ISOQUINOLINES;

EID: 33746617495     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200600046     Document Type: Article

References (36)

1. a) H. Sorimachi, S. Ishiura, K. Suzuki, Biochem. J. 1997, 328, 721-732;
2. b) D. E. Goll, V. F. Thompson, H. Li, W. Wei, J. Cong, Physiol. Rev. 2003, 83, 731-801.
3. P. Friedrich, Biochem. Biophys. Res. Commun. 2004, 323, 1131-1133.
4. a) J. Janossy, P. Ubezio, A. Apati, M. Magocsi, P. Tompa, P. Friedrich, Biochem. Pharmacol. 2004, 67, 1513-1521;
5. b) A. Wells, A. Huttenlocher, D. A. Lauffenburger, Int. Rev. Cytol. 2005, 245, 1-16.
6. P. Tompa, P. Buzder-Lantos, A. Tantos, A. Farkas, A. Szilagyi, Z. Banoczi, F. Hudecz, P. Friedrich, J. Biol. Chem. 2004, 279, 20 775-20 785, and references therein.
7. Although the degradation of several cytoskeleton proteins such as α-fodrin, actin, and spectrin has been used to gauge the activity of calpain, there is no compelling evidence that any of these proteins is the natural substrate. The high catalytic promiscuity of calpain is manifested in the data in reference [4], in which 49 identified substrates with 106 cleavage sites are compiled. As the authors point out, the actual number of calpain substrates is higher, as evidenced by the growing number of recently published papers that report the hydrolysis of natural proteins catalyzed by calpain.
8. C. M. Hosfield, J. S. Elce, P. L. Davies, Z. C. Jia, EMBO J. 1999, 18, 6880-6889.
9. As is the case for the various substrates of calpain, there is an increasing number of papers that report the participation of calpain in different physiological and metabolic processes. Therefore, it is not clear which (if any) is the precise physiological role for this protease. However, some the most studied processes include cytoskeleton remodeling, apoptosis and necrosis, cell cycle, and cell motility. For some reviews, see reference [3].
10. S. M. Harwood, M. M. Yaqoob, D. A. Allen, Ann. Clin. Biochem. 2005, 42, 415-431, and references therein.
11. a) Y. H. Huang, K. K. W. Wang, Trends Mol. Med. 2001, 7, 355-362;
12. b) M. Zatz, A. Starling, N. Engl. J. Med. 2005, 352, 2413-2423.
13. a) K. K. W. Wang, P. Yuen, Adv. Pharmacol. 1996, 37, 117-152;
14. b) I. O. Donkor, Curr. Med. Chem. 2000, 7, 1171-1188;
15. ) A. T. Neffe, A. D. Abell, Curr. Opin. Drug Discovery Dev. 2005, 8, 684-700.
16. For reports on non-electrophilic calpain inhibitors with aromatic rings, see: a) W. Wan, P. B. DePetrillo, Biochem. Pharmacol. 2002, 63, 1481-1484;
17. b) A. Montero, E. Mann, A. Chana, B. Herradón, Chem. Biodiversity 2004, 1, 442-457;
18. ) A. Montero, M. Alonso, E. Benito, A. Chana, E. Mann, J. M. Navas, B. Herradón, Bioorg. Med. Chem. Lett. 2004, 14, 2753-2757;
19. ) A. Montero, F. Albericio, M. Royo, B. Herradón, Org. Lett. 2004, 6, 4089-4092;
20. e) A. Montero, E. Mann, B. Herradón, Tetrahedron Lett. 2005, 46, 401-405.
21. E. Mann, A. Chana, F. Sánchez-Sancho, C. Puerta, A. García-Merino, B. Herradón, Adv. Synth. Catal. 2002, 344, 855-867.
22. The decision to use the sec-butyl group at C3 was taken on the basis that the four diastereomers of 2-amino-3-methyl-butanoic acid are readily available.
23. a) F. Sánchez-Sancho, E. Mann, B. Herradón, Synlett 2000, 509-513;
24. b) F. Sánchez-Sancho, E. Mann, B. Herradón, Adv. Synth. Catal. 2001, 343, 360-368.
25. 13C NMR, MS, IR) and analytical (C, H, N, ± 0.30%) methods.
26. For recent reviews on the Heck reaction, see: a) A. B. Dounay, L. E. Overman, Chem. Rev. 2003, 103, 2945-2963;
27. b) M. Shibasaki, E. M. Vogl, T. Ohshima, Adv. Synth. Catal. 2004, 346, 1533-1552;
28. ) V. Farina, Adv. Synth. Catal. 2004, 346, 1553-1582.
29. M. M. Abelman, T. Oh, L. E. Overman, J. Org. Chem. 1987, 52, 4130-4133.
30. These peptides were prepared by standard methodology by using N-Boc and methyl ester protection. The coupling step was realized with the combination of 1-hydroxybenzotriazole (HOBT), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and 4-(dimethylamino)pyridine (DMAP).
31. a) B. Lygo in Handbook of Reagents for Organic Synthesis. Activating Agents and Protecting Groups (Eds.: A. J. Pearson, W. R. Roush), Wiley, Chichester, 1999, pp. 220-222;
32. b) P. Lloyd-Williams, F. Albericio, E. Giralt, Chemical Approaches to the Synthesis of Peptides and Proteins, CRC, Boca Raton, 1997.
33. V. F. Thomson, S. Saldaña, J. Cong, D. E. Goll, Anal. Biochem. 2000, 279, 170-178.
34. 50 values.
35. S. Chatterjee, M. Iqbal, J. C. Kauer, J. P. Mallamo, S. Senadhi, S. Mallya, D. Bozyczko-Coyne, R. Siman, Bioorg. Med. Chem. Lett. 1996, 6, 1619-1622, and references cited therein.
36. 2+-mediated activation of calpain.